Summary:
This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.
Inclusion Criteria:
- Patients with a Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnosis of schizophrenia or schizoaffective disorder as confirmed by the Mini International Neuropsychiatric Interview (MINI)
- Medically stable during the six months prior to study entry
- Outpatient with no hospitalization for worsening of schizophrenia or schizoaffective disorder within six months prior to study entry
- PANSS negative symptom factor score of 18 or higher
- The following rating on items of the PANSS: (a) less than 5 on G8 (uncooperativeness), P1 (delusions), P3 (hallucinations), P4 (excitement/hyperactivity), and P6 (suspiciousness/persecution); (b) less than 4 on P7 (hostility), and G14 (poor impulse control)
- Has an informant who is considered reliable by the Investigator
- Part B only: Stable treatment with a dopamine/serotonin (D2/5HT2A) antagonist or a D2 partial agonist for a minimum of 6 months and receiving no more than two antipsychotics
Qualified Participants May Receive:
Monetary compensation and study-related care at no cost to the participant.